IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
A phase 1/2 trial of IN10018 in ovarian cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.
Overview
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT05551507 by InxMed (Shanghai) Co., Ltd., with 150 participants planned, started 2020-07-27 and due to reach its primary completion in 2026-05-31. Interventions recorded: IN10018 in combination with PLD. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018 in Combination With Standard Chemotherapy in Subjects With High-grade Serous Epithelial Ovarian Cancer
Phase
Phase 1/2
Sponsor
InxMed (Shanghai) Co., Ltd.
Registry
Enrolled
150
Similar pages
not linked directly; found by shared links- TrialIN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren
Shares InxMed (Shanghai), IN10018, Ovarian cancer.
- TrialA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Shares InxMed (Shanghai), IN10018.
- TrialIN10018 Combination Therapy in Treatment-naïve ES-SCLC
Shares InxMed (Shanghai), IN10018.
- CompanyInxMed
Shares IN10018, Ovarian cancer.